Relapsed and refractory multiple myeloma is a cancer that originates in plasma cells of the bone marrow and is generally considered to be incurable. In recent years, various combination therapies have been approved for this disease, which can prolong the life expectancy of those affected. While most medications are administered intravenously, to date there is only one oral form of administration.
As a recent study by the WifOR Institute and Takeda Pharma Vertrieb GmbH & Co. KG with the assistance of SIBE Professor Dr. Dennis Ostwald was able to show, oral therapies have a cost advantage over intravenous treatments. The financial impact is mainly due to the level of drug prices and the duration of therapy.
Read the full article in the renowned journal “The European Journal of Health Economics“.